MX366341B - Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. - Google Patents
Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.Info
- Publication number
- MX366341B MX366341B MX2015017609A MX2015017609A MX366341B MX 366341 B MX366341 B MX 366341B MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 366341 B MX366341 B MX 366341B
- Authority
- MX
- Mexico
- Prior art keywords
- peptidomimetics
- peptides
- treatments
- cancer patient
- combination uses
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000816 peptidomimetic Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000010261 cell growth Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000012820 cell cycle checkpoint Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a compuestos que incluyen péptidos y peptidomiméticos que se pueden usar para tratar trastornos proliferativos, tales como los asociados con células de tumores benignos y malignos. Mientras la invención no se limita a ningún mecanismo particular, los compuestos de la invención pretenden funcionar al menos parcialmente inhibiendo el punto de control del Ciclo celular G2. Entonces, los compuestos de la invención se pueden usar para inhibir solo el crecimiento celular o se puede usar en combinación con un tratamiento de daño de ácido nucleico para inhibir el crecimiento celular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838777P | 2013-06-24 | 2013-06-24 | |
| PCT/IB2014/001579 WO2014207556A1 (en) | 2013-06-24 | 2014-06-24 | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015017609A MX2015017609A (es) | 2016-04-15 |
| MX366341B true MX366341B (es) | 2019-07-05 |
Family
ID=52141164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017609A MX366341B (es) | 2013-06-24 | 2014-06-24 | Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9221872B2 (es) |
| EP (1) | EP3013351B1 (es) |
| JP (1) | JP6401255B2 (es) |
| KR (1) | KR102247493B1 (es) |
| CN (1) | CN105324121A (es) |
| AU (1) | AU2014300713B2 (es) |
| BR (1) | BR112015032542A2 (es) |
| CA (1) | CA2916136C (es) |
| CL (1) | CL2015003704A1 (es) |
| CY (1) | CY1122523T1 (es) |
| DK (1) | DK3013351T3 (es) |
| ES (1) | ES2765300T3 (es) |
| HR (1) | HRP20192264T1 (es) |
| HU (1) | HUE046873T2 (es) |
| IL (1) | IL243266B (es) |
| LT (1) | LT3013351T (es) |
| MX (1) | MX366341B (es) |
| MY (1) | MY182232A (es) |
| PH (1) | PH12015502855B1 (es) |
| PL (1) | PL3013351T3 (es) |
| PT (1) | PT3013351T (es) |
| RS (1) | RS60180B1 (es) |
| RU (1) | RU2732440C2 (es) |
| SG (1) | SG11201510490VA (es) |
| SI (1) | SI3013351T1 (es) |
| WO (1) | WO2014207556A1 (es) |
| ZA (1) | ZA201600089B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| AU2014232954B2 (en) | 2013-03-15 | 2018-08-09 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
| KR102787208B1 (ko) | 2014-05-16 | 2025-03-27 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
| BR112017001010A2 (pt) | 2014-07-17 | 2017-11-14 | Protagonist Therapeutics Inc | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| BR112017006826A2 (pt) | 2014-10-01 | 2017-12-12 | Protagonist Therapeutics Inc | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| PL3464336T3 (pl) | 2016-06-01 | 2022-05-16 | Athira Pharma, Inc. | Związki |
| WO2019051494A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND USES THEREOF |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| TW202515892A (zh) | 2020-01-15 | 2025-04-16 | 美商健生生物科技公司 | 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途 |
| KR20220141808A (ko) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
| CA3202226A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN116139252B (zh) * | 2021-08-10 | 2025-04-22 | 昆明医科大学 | 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995135B2 (en) * | 2002-01-17 | 2006-02-07 | Canbas Co., Ltd. | Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| CA2503730C (en) * | 2002-10-31 | 2011-10-18 | Metabasis Therapeutics, Inc. | Cytarabine monophosphate prodrugs |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| JP4705567B2 (ja) * | 2003-06-25 | 2011-06-22 | 株式会社 キャンバス | 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物 |
| AR071774A1 (es) * | 2008-05-14 | 2010-07-14 | Takeda Pharmaceutical | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. |
-
2014
- 2014-06-24 SI SI201431451T patent/SI3013351T1/sl unknown
- 2014-06-24 WO PCT/IB2014/001579 patent/WO2014207556A1/en not_active Ceased
- 2014-06-24 CN CN201480035471.4A patent/CN105324121A/zh active Pending
- 2014-06-24 ES ES14818523T patent/ES2765300T3/es active Active
- 2014-06-24 MX MX2015017609A patent/MX366341B/es active IP Right Grant
- 2014-06-24 DK DK14818523.4T patent/DK3013351T3/da active
- 2014-06-24 PT PT148185234T patent/PT3013351T/pt unknown
- 2014-06-24 SG SG11201510490VA patent/SG11201510490VA/en unknown
- 2014-06-24 JP JP2016520755A patent/JP6401255B2/ja active Active
- 2014-06-24 PL PL14818523T patent/PL3013351T3/pl unknown
- 2014-06-24 BR BR112015032542A patent/BR112015032542A2/pt not_active Application Discontinuation
- 2014-06-24 AU AU2014300713A patent/AU2014300713B2/en active Active
- 2014-06-24 LT LTEP14818523.4T patent/LT3013351T/lt unknown
- 2014-06-24 KR KR1020157036784A patent/KR102247493B1/ko active Active
- 2014-06-24 RS RS20191687A patent/RS60180B1/sr unknown
- 2014-06-24 MY MYPI2015704731A patent/MY182232A/en unknown
- 2014-06-24 RU RU2016101718A patent/RU2732440C2/ru active
- 2014-06-24 HU HUE14818523A patent/HUE046873T2/hu unknown
- 2014-06-24 EP EP14818523.4A patent/EP3013351B1/en active Active
- 2014-06-24 HR HRP20192264TT patent/HRP20192264T1/hr unknown
- 2014-06-24 US US14/313,264 patent/US9221872B2/en active Active
- 2014-06-24 CA CA2916136A patent/CA2916136C/en active Active
-
2015
- 2015-12-21 IL IL24326615A patent/IL243266B/en active IP Right Grant
- 2015-12-22 PH PH12015502855A patent/PH12015502855B1/en unknown
- 2015-12-22 CL CL2015003704A patent/CL2015003704A1/es unknown
-
2016
- 2016-01-06 ZA ZA2016/00089A patent/ZA201600089B/en unknown
-
2019
- 2019-12-23 CY CY20191101352T patent/CY1122523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502855B1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
| ZA201802966B (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| SG10201902380SA (en) | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases | |
| PH12014500248B1 (en) | Treatment of breast cancer | |
| EP4424326A3 (en) | Modified nk-92 cells for treating cancer | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
| AU2015279834A8 (en) | Use of peptides that block metadherin-SND1 interaction as treatment for cancer | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| MX377618B (es) | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
| NZ627480A (en) | Inhibitors of iap | |
| SG10201902568YA (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
| PH12021550035A1 (en) | Combination therapy | |
| MX359337B (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
| PH12016000355B1 (en) | Use of xanthophylls for the treatment of cancers | |
| UA78354U (ru) | Способ лечения базально-клеточного рака кожи | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| EA201892813A1 (ru) | Иммунотерапия рака | |
| IN2015KN00676A (es) | ||
| NZ748422A (en) | Heterocyclic glutaminase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |